| 299 |
12-Months Follow-Up of TAXUS & Cypher Stent; Results from the MAHI Database |
Barry D. Rutherford |
Jun. 01. 07 |
| 298 |
Drug-Eluting Stents: Are They Equal in Efficacy and Safety? |
Albert Schömig |
Jun. 01. 07 |
| 297 |
Should Everybody Get DES? |
Augusto D. Pichard |
Jun. 01. 07 |
| 296 |
REWARDS: Non- Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in the Real World: 1-Year Results From a Large, Single Center Registry |
Ron Waksman |
May. 25. 07 |
| 295 |
ACUITY: One Year Outcome of ACUITY Trial |
Roxana Mehran |
May. 25. 07 |
| 294 |
ZOMAXX I: A Prospective, Multicenter, Randomized Trial of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease: 9-Month Clinical and Angiographic Results |
Bernard R. Chevalier |
May. 25. 07 |
| 293 |
SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease |
Gregg W. Stone |
May. 25. 07 |
| 292 |
Drug-Eluting Stent Restenosis: First Large, Multicenter Prospective Report of Treatment Strategies and Clinical Outcomes in the US From the Strategic Transcatheter Evaluation of New Therapies (STENT) Group |
Charles A. Simonton |
May. 25. 07 |
| 291 |
DECLARE-Diabetes: Drug Eluting Stent Followed by Cilostazol Treatment Reduces Late Restenosis in Patient with Diabetes Mellitus |
Seong-Wook Park |
May. 25. 07 |
| 290 |
ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results |
Gregg W. Stone |
May. 25. 07 |
